The 36 references in paper E. Barabanova N., Е. Барабанова Н. (2016) “ПЕРСОНАЛИЗИРОВАННЫЙ ПОДХОД, ДОКАЗАТЕЛЬСТВА, ПРАКТИКА (ПО МАТЕРИАЛАМ XXVI НАЦИОНАЛЬНОГО КОНГРЕССА ПО БОЛЕЗНЯМ ОРГАНОВ ДЫХАНИЯ) // INDIVIDUALIZED APPROACH, EVIDENCE, PRACTICE (BASED ON PROCEEDINGS OF THE 26TH NATIONAL CONGRESS ON RESPIRATORY DISEASES)” / spz:neicon:pulmonology:y:2016:i:5:p:630-634

1
Herland K., Akselsen J.P., Skjø′nsberg O.H. et al. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease?Respir. Med. 2005; 99: 11–19.
(check this in PDF content)
2
Treweek S., Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials. 2009; 10: 37.
(check this in PDF content)
3
Godwin M., Ruhland L., Casson I. et al. Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. BMC Med. Res. Methodol. 2003; 3: 28.
(check this in PDF content)
4
ABPI. The Vision for Real World Data – Harnessing the opportunities in the UK. White Paper, September 2011. URL: http://www.abpi.org.uk/our$work/library/industry/Documents/ Vision$for$Real$World$Data.pdf(дата обращения 02.12.16).
(check this in PDF content)
5
Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.Am. J. Respir. Crit. Care Med. 2004; 170: 836–844.
(check this in PDF content)
6
Busse W.W., Shailen R.S., Somerville L. et al. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients. J.Allergy Clin. Immunol.2008; 121 (6): 1407–1414. DOI: 10.1016/j.jaci.2008.03.019.
(check this in PDF content)
7
Vestbo J., Anderson J.A., Calverley P.M.A. et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009; 64: 939–943.
(check this in PDF content)
8
Papi A., Paggiaro P.L., Nicolini G. et al. Inhaled Combination Asthma Treatment versus SYmbicort (ICAT SY) Study Group: beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur. Respir. J. 2007; 29: 682–689.
(check this in PDF content)
9
Breekveldt-Postma N.S., Koerselman J., Erkens J.A. et al. Treatment with inhaled corticosteroids in asthma is too often discontinued. Pharmacoepidemiol. Drug Saf.2008; 17: 411–422.
(check this in PDF content)
10
Janson C., de Marco R., Accordini S. et al. Changes in the use of anti-asthmatic medication in an international cohort.Eur. Respir. J.2005; 26: 1047–1055.
(check this in PDF content)
11
Adams R.J., Fuhlbrigge A., Guilbert T. et al. Inadequate use of asthma medication in the United States: Results of the asthma in America national population survey. J. Allergy Clin. Im$ munol.2002; 110: 58–64.
(check this in PDF content)
12
Ställberg B., Nystrom K.U., Olsson P. et al. Living with asthma in Sweden – the ALMA study. Respir. Med.2003; 97: 835–843.
(check this in PDF content)
13
Marco R., Cazzoletti L., Cerveri I. et al. Are the asthma guideline goals achieved in daily practice? A population-based study on treatment adequacy and the control of asthma. Int. Arch. Allergy Immunol. 2005; 138: 225–234.
(check this in PDF content)
14
Corrigan C.J. Asthma therapy: there are guidelines, and then there is real life.Prim. Care Respir. J. 2011; 20: 13–14.
(check this in PDF content)
15
Vestbo J., Leather D., Bakerly N.D. et al. Effectiveness of fluticasone furoate–vilanterol for COPD in clinical practice. N. Eng. J. Med. 2016; 375: 1253–1260.
(check this in PDF content)
16
Agusti A., Calverley P.M., Celli B. et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir. Res. 2010; 11: 122.
(check this in PDF content)
17
Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. GOLD, 2016. URL: www.goldcopd.com
(check this in PDF content)
18
Casanova C., Marin J.M., Martinez-Gonzalez C. et al. New GOLD classification: longitudinal data on group assignment. Respir. Res.2014; 15: 3–12.
(check this in PDF content)
19
Nannini L.J., Lasserson T.J., Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.2012; 9: CD006829.
(check this in PDF content)
20
Nannini L.J., Poole P., Milan S.J. et al. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease.Cochrane Database Syst. Rev.2013; 8: CD006826.
(check this in PDF content)
21
Dransfield M.T., Bourbeau J., Jones P.W. et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir. Med. 2013; 1: 210–223.
(check this in PDF content)
22
Sharafkhaneh A., South J.G., Goldman M. et al. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.Respir Med.2012; 106: 257–268.
(check this in PDF content)
23
Wedzicha J.A., Singh D., Vestbo J. et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations.Respir. Med. 2014; 108: 1153–1162.
(check this in PDF content)
24
Kardos P., Wencker M., Glaab T. et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care Med. 2007; 175: 144–149.
(check this in PDF content)
25
EMA completes review of inhaled corticosteroids for chronic obstructive pulmonary disease. EMA/488280/2016. URL: http://www.ema.europa.eu/docs/en_GB/document_library/ Referrals_document/Inhaled_corticosteroids_Article_31/European_ Commission_final_decision/WC500210489.pdf
(check this in PDF content)
26
Siddiqui S.H., Guasconi A., Vestbo J. et al. Blood Eosinophils: A biomarker of response to extrafine beclomethasone/ formoterol in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.2015; 192: 523–525.
(check this in PDF content)
27
Pascoe S., Locantore N., Dransfield M.T. et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: A secondary analysis of data from two parallel randomised controlled trials. Lancet Respir. Med. 2015; 3: 435–442.
(check this in PDF content)
28
Pavord I.D., Lettis S., Locantore N. et al. Blood eosinophils and inhaled corticosteroid/long-acting β2-agonist efficacy in COPD. Thorax. 2016; 7: 118–125.
(check this in PDF content)
29
Watz H., Tetzlaff K., Wouters E.F.M. et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.Lancet Respir. Med. 2016; 4: 390–398.
(check this in PDF content)
30
MüllerováH., Lu C., Li H. et al. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease. PLoS ONE.2014; 9 (1): e85540.
(check this in PDF content)
31
Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur. Respir. J. 2015; 45: 869–871.
(check this in PDF content)
32
Bateman E.D., Ferguson G.T., Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study.Eur. Respir. J.2013; 42: 1484–1494.
(check this in PDF content)
33
Maleki-Yazdi M.R., Kaelin T., Richard N. et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.Respir. Med. 2014; 108: 1752–1760.
(check this in PDF content)
34
Maleki-Yazdi M.R., Singh D., Anzueto A. et al. Assessing short-term deterioration in maintenance-naїve patients with COPD receiving umeclidinium/vilanterol and tiotropium: a pooled analysis of three randomized trials. Adv. Ther.2017; 33: 2188–2199. Epub. Oct. 28, 2016.
(check this in PDF content)
35
Calzetta L., Matera M.G., Cazzola M. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. Eur. J. Pharmacol. 2015; 761:168–173.
(check this in PDF content)
36
Agusti A. The path to personalized medicine in COPD. Thorax. 2014; 69: 857–864. Поступила 09.11.16 УДК 616.2(063) Received November 09, 2016
(check this in PDF content)